CRISPR Therapeutics AG (CRSP) Revenue (2016 - 2026)

CRISPR Therapeutics AG has disclosed Revenue across 11 years of filings, most recently posting $1.5 million for Q1 2026.

• Revenue for Q1 2026 came in at $1.5 million, up 68.55% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.1 million (down 89.11% YoY), and the FY2025 annual result was $3.5 million, down 90.59% from the prior year.
• Revenue came in at $1.5 million for Q1 2026 at CRISPR Therapeutics AG, up from $864000.0 in the prior quarter.
• In the past five years, Revenue ranged from a high of $201.2 million in Q4 2023 to a low of $6000.0 in Q4 2022.
• The 5-year median for Revenue is $877000.0 (2025), against an average of $25.9 million.
• Across the five-year window, Revenue sank 99.98% in 2022 and soared 3353333.33% in 2023, its largest moves.
• CRISPR Therapeutics AG's Revenue stood at $6000.0 in 2022, then jumped by 3353333.33% to $201.2 million in 2023, then slumped by 82.26% to $35.7 million in 2024, then tumbled by 97.58% to $864000.0 in 2025, then surged by 68.75% to $1.5 million in 2026.
• The last three Revenue figures came in at $1.5 million (Q1 2026), $864000.0 (Q4 2025), and $889000.0 (Q3 2025), per Business Quant data.